Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
SGEN's Cash to Debt is ranked higher than
93% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.62 vs. SGEN: No Debt )
SGEN' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.48
SGEN's Equity to Asset is ranked higher than
61% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. SGEN: 0.48 )
SGEN' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.96
Current: 0.48

0.36
0.96
Interest Coverage No Debt
SGEN's Interest Coverage is ranked higher than
79% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SGEN: No Debt )
SGEN' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 9.48
M-Score: -3.56
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -26.72
SGEN's Operating margin (%) is ranked higher than
76% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -57.52 vs. SGEN: -26.72 )
SGEN' s 10-Year Operating margin (%) Range
Min: -9958.59   Max: -23.35
Current: -26.72

-9958.59
-23.35
Net-margin (%) -26.64
SGEN's Net-margin (%) is ranked higher than
76% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -55.49 vs. SGEN: -26.64 )
SGEN' s 10-Year Net-margin (%) Range
Min: -7917.17   Max: -23.22
Current: -26.64

-7917.17
-23.22
ROE (%) -31.61
SGEN's ROE (%) is ranked higher than
71% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -27.70 vs. SGEN: -31.61 )
SGEN' s 10-Year ROE (%) Range
Min: -128.57   Max: -24.17
Current: -31.61

-128.57
-24.17
ROA (%) -15.43
SGEN's ROA (%) is ranked higher than
75% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -20.88 vs. SGEN: -15.43 )
SGEN' s 10-Year ROA (%) Range
Min: -50.86   Max: -12
Current: -15.43

-50.86
-12
ROC (Joel Greenblatt) (%) -190.42
SGEN's ROC (Joel Greenblatt) (%) is ranked higher than
73% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -212.10 vs. SGEN: -190.42 )
SGEN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -903.49   Max: -191.83
Current: -190.42

-903.49
-191.83
Revenue Growth (%) 27.80
SGEN's Revenue Growth (%) is ranked higher than
92% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. SGEN: 27.80 )
SGEN' s 10-Year Revenue Growth (%) Range
Min: 7.3   Max: 157.1
Current: 27.8

7.3
157.1
EBITDA Growth (%) -11.10
SGEN's EBITDA Growth (%) is ranked higher than
73% of the 634 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. SGEN: -11.10 )
SGEN' s 10-Year EBITDA Growth (%) Range
Min: -30.2   Max: 18
Current: -11.1

-30.2
18
EPS Growth (%) -8.20
SGEN's EPS Growth (%) is ranked higher than
77% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. SGEN: -8.20 )
SGEN' s 10-Year EPS Growth (%) Range
Min: -34   Max: 27.9
Current: -8.2

-34
27.9
» SGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

SGEN Guru Trades in Q3 2013

Steven Cohen 44,608 sh (+26.58%)
PRIMECAP Management 10,887,000 sh (-0.01%)
Columbia Wanger 7,547,000 sh (-7.11%)
Jim Simons 339,213 sh (-15.62%)
Manning & Napier Advisors, Inc 381,140 sh (-28.41%)
» More
Q4 2013

SGEN Guru Trades in Q4 2013

PRIMECAP Management 10,953,400 sh (+0.61%)
Manning & Napier Advisors, Inc 369,210 sh (-3.13%)
Columbia Wanger 6,701,000 sh (-11.21%)
Steven Cohen 28,354 sh (-36.44%)
Jim Simons 126,013 sh (-62.85%)
» More
Q1 2014

SGEN Guru Trades in Q1 2014

Ray Dalio 22,400 sh (New)
Jim Simons 268,713 sh (+113.24%)
PRIMECAP Management 11,007,005 sh (+0.49%)
Columbia Wanger 6,626,000 sh (-1.12%)
Manning & Napier Advisors, Inc 272,980 sh (-26.06%)
Steven Cohen 16,034 sh (-43.45%)
» More
Q2 2014

SGEN Guru Trades in Q2 2014

Manning & Napier Advisors, Inc 399,490 sh (+46.34%)
Ray Dalio Sold Out
Jim Simons Sold Out
Columbia Wanger 6,610,000 sh (-0.24%)
PRIMECAP Management 10,895,800 sh (-1.01%)
» More
» Details

Insider Trades

Latest Guru Trades with SGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ray Dalio 2014-06-30 Sold Out 0.01%$32.82 - $46.79 $ 35.25-7%0
Ray Dalio 2014-03-31 New Buy0.01%$38.57 - $55.14 $ 35.25-26%22400
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 19.50
SGEN's P/B is ranked higher than
60% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.62 vs. SGEN: 19.50 )
SGEN' s 10-Year P/B Range
Min: 1.64   Max: 29.21
Current: 19.5

1.64
29.21
P/S 15.90
SGEN's P/S is ranked higher than
76% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.28 vs. SGEN: 15.90 )
SGEN' s 10-Year P/S Range
Min: 9.98   Max: 64.56
Current: 15.9

9.98
64.56
EV-to-EBIT -55.34
SGEN's EV-to-EBIT is ranked higher than
57% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SGEN: -55.34 )
SGEN' s 10-Year EV-to-EBIT Range
Min: 68.7   Max: 92.9
Current: -55.34

68.7
92.9
Current Ratio 4.07
SGEN's Current Ratio is ranked higher than
74% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.07 vs. SGEN: 4.07 )
SGEN' s 10-Year Current Ratio Range
Min: 2.75   Max: 30.03
Current: 4.07

2.75
30.03
Quick Ratio 3.78
SGEN's Quick Ratio is ranked higher than
74% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. SGEN: 3.78 )
SGEN' s 10-Year Quick Ratio Range
Min: 2.75   Max: 30.03
Current: 3.78

2.75
30.03

Valuation & Return

vs
industry
vs
history
Price/Net Cash 41.00
SGEN's Price/Net Cash is ranked higher than
77% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 100.00 vs. SGEN: 41.00 )
SGEN' s 10-Year Price/Net Cash Range
Min: 2.12   Max: 56.4
Current: 41

2.12
56.4
Price/Net Current Asset Value 29.60
SGEN's Price/Net Current Asset Value is ranked higher than
76% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 45.54 vs. SGEN: 29.60 )
SGEN' s 10-Year Price/Net Current Asset Value Range
Min: 2.11   Max: 535
Current: 29.6

2.11
535
Price/Tangible Book 19.30
SGEN's Price/Tangible Book is ranked higher than
65% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 8.50 vs. SGEN: 19.30 )
SGEN' s 10-Year Price/Tangible Book Range
Min: 1.78   Max: 24.23
Current: 19.3

1.78
24.23
Price/Median PS Value 0.70
SGEN's Price/Median PS Value is ranked higher than
91% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 1.80 vs. SGEN: 0.70 )
SGEN' s 10-Year Price/Median PS Value Range
Min: 0.47   Max: 25.91
Current: 0.7

0.47
25.91
Forward Rate of Return (Yacktman) -13.34
SGEN's Forward Rate of Return (Yacktman) is ranked higher than
74% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -11.47 vs. SGEN: -13.34 )
SGEN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.8   Max: 2.6
Current: -13.34

1.8
2.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SGT.Germany
Seattle Genetics, Inc., a Delaware corporation was incorporated on July 15, 1997. It is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. On August 19, 2011, the U.S. Food and Drug Administration, or FDA, granted accelerated approval of ADCETRISTM, or brentuximab vedotin, in two indications: (1) the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant, or ASCT, or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2) the treatment of patients with systemic anaplastic large cell lymphoma, or sALCL, after failure of at least one prior multi-agent chemotherapy regimen. ADCETRIS is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing the Company's proprietary technology. The Company has a broad development strategy for ADCETRIS evaluating its potential application in earlier lines of therapy in patients with Hodgkin lymphoma and sALCL and other CD30-positive malignancies. In addition, it has four clinical-stage ADC programs, which consist of SGN-75, ASG-5ME, ASG-22ME and SGN-CD19A, as well as several preclinical product candidates, including SGN-CD33A and SGN-LIV1A. The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. Many third parties compete with the Company in developing various approaches to cancer and autoimmune disease therapy. They include pharmaceutical companies, biotechnology companies, academic institutions and other research organizations. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, pre-market approval, manufacture, marketing and distribution of biopharmaceutical products.
» More Articles for SGEN

Headlines

Articles On GuruFocus.com
Seattle Genetics: Can Record Sustained Growth From Royalty Aug 31 2014 
Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
Comment for Companies Ranked by Business Predictability Jan 03 2013 
Weekly CFO Sells Highlight: SGEN, PFIE, MAR, ESRX, LIOX, RGEN Sep 10 2012 
WEEKLY CFO SELLS HIGHLIGHT: SBAC, XOXO, MTH, FICO, SGEN, OAS Sep 03 2012 
Weekly CFO Sells Highlight: SWKS, P, SGEN, RT Jun 11 2012 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Weekly CFO Sells Highlight: SGEN, APKT, AMRC, FNGN Oct 10 2011 
Weekly CEO Sells Highlight: WLL, PDE, HUM, SGEN Mar 20 2011 

More From Other Websites
Stock Weakness in Seattle Genetics, Gilead Sciences Belies Fundamental Strengths Oct 15 2014
Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2014 Financial... Oct 14 2014
Biotech Stock Mailbag: Seattle Genetics, Achillion, Catalyst Pharma Oct 03 2014
The Zacks Analyst Blog Highlights: Super Micro Computer, Horizon Pharma, Phibro Animal Health,... Oct 02 2014
Will This Analyst Downgrade Hurt Seattle Genetics (SGEN) Stock Today? Sep 30 2014
SEATTLE GENETICS INC /WA Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 29 2014
Seattle Genetics Seeks Expanded Use of Lymphoma Drug on Study Win Sep 29 2014
Seattle Genetics and Takeda's cancer drug meets main trial goal Sep 29 2014
Seattle Genetics ADCETRIS phase 3 AETHERA clinical trial top-line results Call scheduled for 8:30 am... Sep 29 2014
Seattle Genetics, Takeda's cancer drug meets main goal in trial Sep 29 2014
Seattle Genetics and Takeda Announce Positive Data from Phase 3 AETHERA Clinical Trial of ADCETRIS®... Sep 29 2014
Seattle Genetics and Takeda Announce Positive Data from Phase 3 AETHERA Clinical Trial of ADCETRIS®... Sep 29 2014
Seattle Genetics to Host Conference Call and Webcast on September 29, 2014 Regarding Top-line Data... Sep 26 2014
Seattle Genetics' Adcetris Positive in Durability Analysis Sep 25 2014
Cramer: What caused today's rally Sep 24 2014
Seattle Genetics Highlights Updated Progression-Free Survival and Overall Survival Data from... Sep 24 2014
Seattle Genetics-Genmab Expand Deal for Antibody Platform Sep 11 2014
Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration Sep 10 2014
Seattle Genetics to Present at Morgan Stanley Healthcare Conference Sep 02 2014
Will Seattle Genetics (SGEN) Crush Estimates at Its Next Earnings Report? Aug 29 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK